Clozapine monitoring
Executive Summary
FDA's Psychopharmacologic Drugs Advisory Committee will meet June 16 to discuss the white blood cell monitoring schedule for patients on long-term clozapine (Novartis' Clozaril, generics) therapy. The committee will consider whether the frequency of monitoring can be decreased following "some period of bi-weekly monitoring." Labeling for the atypical antipsychotic recommends weekly monitoring for the first six months of continuous therapy and biweekly monitoring thereafter due to the risk of agranulocytosis. The meeting will be held June 16 at the Marriott Washingtonian Center in Gaithersburg, Md. beginning at 8 a.m. [To watch a live or archived 1webcast of this meeting, go to FDAAdvisoryCommittee.com. To arrange for live videoconferencing or to order videotapes and CDs, email [email protected] or call 800-332-1370 ext. 7210]....
You may also be interested in...
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.